January 18, 2008 -- Sundia MediTech Company, a Shanghai-based CRO, has completed its second round of capital funding, though the amount raised was not disclosed. Sundia said that the fund raising has been underway since last summer, about the time that WuXi PharmaTech (NYSE: WX) made its IPO on the NYSE. Company officials said that the success of the WuXi offering helped Sundia in its efforts. It also didn’t hurt that, last summer, Sundia was also ranked as number 16 on the Venture 50 list, a ranking of the most promising investment opportunities in China put together by Zero2IPO. More details...
